News & Updates
Filter by Specialty:
NAFLD a risk factor for young-onset hypertension
Young people with nonalcoholic fatty liver disease (NAFLD) are at increased risk of hypertension, especially women and those with more severe hepatic steatosis, as shown in a study.
NAFLD a risk factor for young-onset hypertension
09 Jun 2023
Pioglitazone–SGLT2 inhibitor combo delivers for primary CV prevention in diabetes
Combination treatment with pioglitazone plus a sodium-glucose co-transporter 2 (SGLT2) inhibitor helps reduce the risk of developing major adverse cardiovascular events (MACE) and heart failure in individuals with type 2 diabetes mellitus (T2DM) who have no history of cardiovascular disease (CV), as reported in a study.
Pioglitazone–SGLT2 inhibitor combo delivers for primary CV prevention in diabetes
09 Jun 2023
T2DM: SGLT2 inhibitors associated with lower rates of ICU admission and all-cause mortality
A retrospective observational study of nearly 28,000 patients with type 2 diabetes mellitus (T2DM) in Hong Kong finds that use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is independently associated with lower rates of ICU admission and all-cause mortality across various disease categories.
T2DM: SGLT2 inhibitors associated with lower rates of ICU admission and all-cause mortality
07 Jun 2023
Electroporation a promising way to end insulin dependency in T2D
A novel endoscopic electroporation procedure, when combined with semaglutide, can eliminate the need for insulin injections for individuals with type 2 diabetes (T2D), as shown in the results of the first-in-human EMINENT study.
